Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome

British Journal of Haematology

Volumn 118, Issue 4, 2002, Pages 1078-1081

  Heelan, Bridget T ^a   Tormey, Vincent ^a   Amlot, Peter ^a   Payne, Elspeth ^a   Mehta, Atul ^a   Webster, A David B ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Autoimmune lymphoproliferative syndrome; FAS; Immune thrombocytopenia; Rituximab; Vincristine

Indexed keywords

ANTIBODY; CD20 ANTIBODY; DEXAMETHASONE; FANSIDAR; FAS ANTIGEN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPENIA; DISEASE COURSE; DRUG EFFECT; HUMAN; HUMAN CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LYMPH NODE BIOPSY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; PARESTHESIA; PRIORITY JOURNAL; SPLENECTOMY; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AUTOIMMUNE DISEASES; CHILD; COMBINED MODALITY THERAPY; HUMANS; IMMUNOGLOBULIN G; LYMPHOPROLIFERATIVE DISORDERS; MALE; MUTATION; PLATELET COUNT; PROTEINS; THROMBOCYTOPENIA; TNF RECEPTOR-ASSOCIATED FACTOR 6; VINCRISTINE;

EID: 0036046116     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03753.x     Document Type: Article

References (11)

1. Rituximab inactivates signal transducer and activation of transcription 3 (stat3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of bcl-2 and sensitization to cytotoxic drugs
2. Chronic lymphadenopathy simulating malignant lymphoma
3. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
4. Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia
5. Increases in circulating and lymphoid tissue interleukin 10 in autoimmune lymphoproliferative syndrome are associated with disease expression
6. Rituximab dose-escalation trial in chronic lymphocytic leukemia
7. Refractory autoimmune thrombocytopenic purpura treatment with Rituximab
8. Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation
9. The use of the anti-malaria drug fansidar (pyrimethamine and sulphadoxine) in the treatment of a patient with auto-immune lymphoproliferative syndrome and Fas deficiency
10. Chemotherapy sensitization by rituximab: Experimental and clinical evidence
11. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia